Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

Similar Items

• Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
  od: Smolen, Josef S, i dr.
  Izdano: (2015)
• Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
  od: Smolen, Josef S, i dr.
  Izdano: (2014)
• Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody
  od: Pichler, Judith, i dr.
  Izdano: (2020)
• Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
  od: Kirkham, Bruce W, i dr.
  Izdano: (2014)
• Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
  od: Rahman, Mahboob U, i dr.
  Izdano: (2011)